NCT04714827 - Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2025

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

KQ-2003 CAR-T cells

A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .

Trial Locations (1)

030013

RECRUITING

Hematology Department of ShanXi Cancer Hospital, Taiyuan